RP-HPLC analysis of flucloxacillin in human plasma: Validation and application to a bioequivalence study

Pharmazie

Volumn 62, Issue 2, 2007, Pages 101-104

  Zhou, Q ^a   Ruan, Zourong ^a   Yuan, H ^a   Jiang, B ^a   Xu, D ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYMETHYLFLUCLOXACILLIN; ACETIC ACID; ACETONITRILE; DICLOXACILLIN; DRUG METABOLITE; FLUCLOXACILLIN; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEVICE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; PRECIPITATION; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE;

ADULT; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FLOXACILLIN; HUMANS; INDICATORS AND REAGENTS; MALE; PENICILLINS; QUALITY CONTROL; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; THERAPEUTIC EQUIVALENCY;

EID: 33847125791     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2007.2.6103     Document Type: Article

References (14)

1. Bal AM, Gould IM (2005) Antibiotic resistance in Staphylococcus aureus and its relevance in therapy. Expert Opin Pharmacother 6: 2257-2269.
2. Bodey GP, Vallejos C, Stewart D (1972) Flucloxacillin: a new semisynthetic isoxazolyl penicillin. Clin Pharmacol Ther 13: 512-515.
3. Charles BG, Foo CC, Gath J (1994) Rapid column liquid chromatographic analysis of flucloxacillin in plasma on a microparticulate pre-column. J Chromatogr B Biomed Appl 660: 186-190.
4. nd ed., revised and expanded. New York, p. 79-124.
5. Food and Drug Administration (1993) In vivo bioequivalence guidances. Pharmacopeial Forum 19: 6501-6508.
6. Frank U, Schmidt-Eisenlohr E, Schlosser V, Spillner G, Schindler M, Daschner FD (1988) Concentrations of flucloxacillin in heart valves and subcutaneous and muscle tissues of patients undergoing open-heart surgery. Antimicrob Agents Chemother 32: 930-931.
7. Hung CT, Lim JK, Zoest AR, Lam FC (1988) Optimization of high-performance liquid chromatographic analysis for isoxazolyl penicillins using factorial design. J Chromatogr 425: 331-341.
8. Nicolau DP (2001) Predicting antibacterial response from pharmacodynamic and pharmacokinetic profiles. Infection 29 (Suppl 2): 11-15.
9. Paton DM, Mander P, Avery RJ (1982) Bioavailability and half-life of two preparations of flucloxacillin. N Z Med J 95: 766-768.
10. Roder BL, Frimodt-Moller N, Espersen F, Rasmussen SN (1995) Dicloxacillin and flucloxacillin: pharmacokinetics, protein binding and serum bactericidal titers in healthy subjects after oral administration. Infection 23: 107-112.
11. Schuirmann DJ (1987) A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 15: 657-680.
12. Steer JA, Papini RP, Wilson AP, McGrouther DA, Parkhouse N (1997) Teicoplanin versus flucloxacillin in the treatment of infection following bums. J Antimicrob Chemother 39: 383-392.
13. Sutherland R, Croydon EAP, Rolinson GN (1970) Flucloxacillin, a new isoxazolyl penicillin, comparaed with oxacillin, cloxacillin, and dicloxacillin. Br Med J 4: 455-460.
14. Turnidge JD (1998) The pharmacodynamics of beta-lactams. Clin Infect Dis 27: 10-22.